A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.
Also called NCT04349072
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 112 participants
- Sponsor
- Registry
-
NCT04349072
-
- Other papers using this trial's data
- Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial
- Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial
- Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study
- Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy
- Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT04349072. Randomized; quadruple masking; primary purpose treatment. Start 2020-07-06 (actual); primary completion 2022-02-07 (actual). Results posted on 2023-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Acronym
- VALOR-HCM
- Condition
- HOCM, Hypertrophic Obstructive Cardiomyopathy
- Intervention (Drug)
- Mavacamten
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct04349072- Content hash
ec5c1671c0410cf458845ead46d3ba389406a73ca61eba1612004d31a6d2e318